5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectal cancer
Bliss E, Robert G
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
Bliss E, Robert G. 5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectal cancer. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1996
Authors' objectives
The authors examine how worthwhile is the proposal that all patients with Duke's stage C colorectal cancer be offered 5-fluorouracil (5-FU) as adjuvant chemotherapy following surgery.
Authors' conclusions
There are undoubted benefits, but in view of side effects the cost of QALYs is likely to be at the upper end of the range.
Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton SO16 7PX. Tel. +44 1703 595661 Fax +44 1703 595662